Literature DB >> 6828969

A prospective random study of a single agent versus combination antibiotics as therapy in penetrating injuries of the abdomen.

C Crenshaw, E Glanges, C Webber, D B McReynolds.   

Abstract

One hundred patients undergoing operation for penetrating and potentially contaminated wounds of the abdomen were given cefamandole or a combination of cephalothin-tobramycin by a random, single blind method as preventive therapy. Results were evaluable for 49 patients receiving cefamandole for a success rate of 93.9 per cent. The 45 evaluable results in the second group had a success rate of 88.9 per cent. Those in the single therapy group also required fewer days of treatment and of hospital confinement, resulting in lower per patient cost. Results of this study show cefamandole to be an efficacious alternative for surgeons seeking a single agent therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6828969

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  4 in total

1.  Prophylaxis in elective colorectal surgery.

Authors:  F Hernàndez Gómez; A Segura Vives; E Basilio Bonet; M A Blasco Blanco; P Caride García; M Galera Rodriguez
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 2.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

3.  Preventative antibiotics for penetrating abdominal trauma--single agent or combination therapy?

Authors:  B A Bivins; L Crots; V J Sorensen; F N Obeid; H M Horst
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Prophylactic antibiotics for penetrating abdominal trauma: duration of use and antibiotic choice.

Authors:  Philip J Herrod; Hannah Boyd-Carson; Brett Doleman; James Blackwell; John P Williams; Ashish Bhalla; Richard L Nelson; Samson Tou; Jon N Lund
Journal:  Cochrane Database Syst Rev       Date:  2019-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.